However, JXD therapy suppressed BLM-induced upregulation of TGF-β, α-SMA, collagen I, fibronectin, and promoted BLM-induced downregulation of E-cadherin, which indicated that JXD may reduce BLM-induced PF via inhibiting TGF-β1 pathway. The gene discussed is TGFB1; the disease is Bloom syndrome.